Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Relapsed/Refractory NHL (MCL, DLBCL, FL)
NCT02413489Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of daratumumab in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Janssen Pharmaceutical. Started Sep 2015; status: terminated.
02
Drugs
daratumumab
03
Conditions
mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02413489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413489.